linezolid + vancomycin (University of Florida)

Linezolid + vancomycin refers to the MRSA-active component of an aggressive empiric antibiotic regimen evaluated by the University of Florida in a Phase 2 clinical trial (NCT00866099). This regimen was designed to treat hospitalized patients with pneumonia requiring mechanical ventilation, with the goal of minimizing the emergence of antimicrobial resistance in pathogens like P. aeruginosa and Acinetobacter spp. Linezolid is an oxazolidinone antibiotic that prevents the formation of the 70S initiation complex by binding to the 23S ribosomal RNA of the 50S subunit, thereby inhibiting protein synthesis. Vancomycin is a glycopeptide antibiotic that inhibits the second stage of bacterial cell wall synthesis by binding with high affinity to the D-alanyl-D-alanine portion of cell wall precursors, preventing peptidoglycan polymerization. In the University of Florida protocol, these agents were used as options for Gram-positive coverage alongside optimized meropenem and aminoglycosides.

Other names

linezolid or vancomycin